Dabigatran - the blood-thinning drug is associated with a higher risk of myocardial infarction (heart attack) or acute coronary syndrome, reveals study published in Archives of Internal Medicine.
"Clinicians should consider the potential of these serious harmful cardiovascular effects with use of dabigatran," the study concludes.
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to avoid heart attack are listed.
Advertisement
Dabigatran etexilate was approved by the European Medicines Agency in 2008 for prevention of venous thromboembolism (VTE) in adults who have undergone total hip or knee replacement and by the U.S. Food and Drug Administration in 2010 for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF), the authors write as background in the study. An original trial suggested a small increased risk of myocardial infarction (MI) with the use of dabigatran compared to warfarin in patients with atrial fibrillation.
Ken Uchino, M.D., and Adrian V. Hernandez, M.D., Ph.D., of the Cleveland Clinic in Ohio, searched the medical literature for randomized controlled trials of dabigatran that reported on MI or acute coronary syndrome (ACS) as secondary outcomes. Seven trials were selected, involving 30,514 participants, for their meta-analysis.
![Quiz on Heart Attack]( "Quiz on Heart Attack")
The risk factors that work behind the scene before a heart attack are familiar to many. But do you realize the extent to which your lifestyle choices are putting your life at risk? Can you identify a heart attack when it occurs? Take our quiz and find out.
The trials they included were: two studies of stroke prophylaxis in atrial fibrillation, one in acute venous thromboembolism, one in ACS and three trials or short-term prophylaxis of deep venous thrombosis in joint replacement. The control groups included administration of warfarin, enoxaparin or placebo.
"Dabigatran was significantly associated with a higher risk of MI or ACS than that seen with agents used in the control group" (dabigatran, 237 events of 20,000 [1.19 percent] vs. control, 83 events of 10,514 [0.79 percent]), the researchers write.
They note the risk of MI or ACS was similar when using revised results of a previous trial and after the exclusion of short-term trials. The authors comment that they used several meta-analytic methods and association measures and the results were consistent.
"Although the relative risk increase was 33 percent, the absolute risk increase was very small, at 0.27 percent," they write.
They suggest that while dabigatran might not directly increase the risk of MI, it may lack the beneficial effects that warfarin and aspirin have in MI prevention. They note they do not know the pharmacologic mechanism that may result in dabigatran increasing the risk of MI or ACS.
"The overall benefit and risk balance of dabigatran use appears to be favorable in patients with AF because of reduction in ischemic stroke. However, the cardiac risk of dabigatran should be investigated further, especially if it is used in populations at high risk of MI or ACS," the authors conclude.
Source: Eurekalert
Quiz on Heart Attack
The risk factors that work behind the scene before a heart attack are familiar to many. But do you realize the extent to which your lifestyle choices are putting your life at risk? Can you identify a heart attack when it occurs? Take our quiz and find out.
Advertisement
The trials they included were: two studies of stroke prophylaxis in atrial fibrillation, one in acute venous thromboembolism, one in ACS and three trials or short-term prophylaxis of deep venous thrombosis in joint replacement. The control groups included administration of warfarin, enoxaparin or placebo.
"Dabigatran was significantly associated with a higher risk of MI or ACS than that seen with agents used in the control group" (dabigatran, 237 events of 20,000 [1.19 percent] vs. control, 83 events of 10,514 [0.79 percent]), the researchers write.
They note the risk of MI or ACS was similar when using revised results of a previous trial and after the exclusion of short-term trials. The authors comment that they used several meta-analytic methods and association measures and the results were consistent.
"Although the relative risk increase was 33 percent, the absolute risk increase was very small, at 0.27 percent," they write.
They suggest that while dabigatran might not directly increase the risk of MI, it may lack the beneficial effects that warfarin and aspirin have in MI prevention. They note they do not know the pharmacologic mechanism that may result in dabigatran increasing the risk of MI or ACS.
"The overall benefit and risk balance of dabigatran use appears to be favorable in patients with AF because of reduction in ischemic stroke. However, the cardiac risk of dabigatran should be investigated further, especially if it is used in populations at high risk of MI or ACS," the authors conclude.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
The FDA advises consumers not to use compounded medications as an alternative to known diabetic and weight reduction medications Ozempic, Rybelsus, and Wegovy.
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.